Short-term high dose steroid therapy does not affect the hypothalamic-pituitary-adrenal axis in relapsing multiple sclerosis patients. Clinical assessment by the insulin tolerance test

被引:25
作者
Levic, Z [1 ]
Micic, D [1 ]
Nikolic, J [1 ]
Stojisavljevic, N [1 ]
Sokic, D [1 ]
Jankovic, S [1 ]
Kendereski, A [1 ]
Mavra, M [1 ]
机构
[1] CLIN CTR SERBIA, INST ENDOCRINOL, YU-11000 BELGRADE, YUGOSLAVIA
关键词
hypothalamic-pituitary-adrenal axis; multiple sclerosis; methylprednisolone; ACTH; cortisol; insulin tolerance test;
D O I
10.1007/BF03347855
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Ten patients in acute exacerbation of multiple sclerosis were treated with 1000 mg of methylprednisolone for 7 days, followed by abrupt cessation of therapy. The function of hypothalamic-pituitary-adrenal (HPA) axis was assessed by the response of ACTH and cortisol to insulin tolerance test (ITT). ITT was performed 1 day before and 1, 3, 8, 13 and 23 days after the termination of the therapy (days 0, 8, 10, 15, 20 and 30 of the study, respectively), The response of these hormones to insulin-induced hypoglycemia prior to therapy was normal. There was no suppression of the ACTH response to hypoglycemia after the methylprednisolone therapy based on the 100% rise of ACTH after ITT, Cortisol response during ITT was suppressed at day 8 (1 day after ending of therapy) but recovered on day 10 (3 days after ending of therapy). In conclusion, 7 day-therapy with 1000 mg methylprednisolone does not result in the permanent suppression of the HPA axis, suggesting that no regular supplemental corticosteroid coverage is required, The observed transitory suppression of the HPA axis recovered spontaneously after the therapy.
引用
收藏
页码:30 / 34
页数:5
相关论文
共 12 条
[1]   INTRAVENOUS METHYLPREDNISOLONE FOR MULTIPLE-SCLEROSIS IN RELAPSE [J].
BARNES, MP ;
BATEMAN, DE ;
CLELAND, PG ;
DICK, DJ ;
WALLS, TJ ;
NEWMAN, PK ;
SAUNDERS, M ;
TILLEY, PJB .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1985, 48 (02) :157-159
[2]   HIGH-DOSE INTRAVENOUS METHYLPREDNISOLONE IN THE TREATMENT OF MULTIPLE-SCLEROSIS - CLINICAL-IMMUNOLOGICAL CORRELATIONS [J].
DURELLI, L ;
COCITO, D ;
RICCIO, A ;
BARILE, C ;
BERGAMASCO, B ;
BAGGIO, GF ;
PERLA, F ;
DELSEDIME, M ;
GUSMAROLI, G ;
BERGAMINI, L .
NEUROLOGY, 1986, 36 (02) :238-243
[3]  
KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444
[4]  
LEVIC Z, 1988, ACTUAL ASPECTS MULTI, P123
[5]  
MIRO J, 1990, ACTA NEUROL SCAND, V81, P524
[6]  
Orth D., 1992, William's Textbook of Endocrinology, P489
[7]   NEW DIAGNOSTIC-CRITERIA FOR MULTIPLE-SCLEROSIS - GUIDELINES FOR RESEARCH PROTOCOLS [J].
POSER, CM ;
PATY, DW ;
SCHEINBERG, L ;
MCDONALD, WI ;
DAVIS, FA ;
EBERS, GC ;
JOHNSON, KP ;
SIBLEY, WA ;
SILBERBERG, DH ;
TOURTELLOTTE, WW .
ANNALS OF NEUROLOGY, 1983, 13 (03) :227-231
[8]   NORMAL AND ABNORMAL FUNCTION OF THE HYPOTHALAMIC-PITUITARY-ADRENOCORTICAL SYSTEM IN MAN [J].
STREETEN, DHP ;
ANDERSON, GH ;
DALAKOS, TG ;
SEELEY, D ;
MALLOV, JS ;
EUSEBIO, R ;
SUNDERLIN, FS ;
BADAWY, SZA ;
KING, RB .
ENDOCRINE REVIEWS, 1984, 5 (03) :371-394
[9]   CORTICOSTEROIDS - CLINICAL PHARMACOLOGY AND THERAPEUTIC USE [J].
SWARTZ, SL ;
DLUHY, RG .
DRUGS, 1978, 16 (03) :238-255
[10]   STEROID-THERAPY IN MULTIPLE-SCLEROSIS - POINT-OF-VIEW [J].
TROIANO, R ;
COOK, SD ;
DOWLING, PC .
ARCHIVES OF NEUROLOGY, 1987, 44 (08) :803-807